British Medical Journal Archives - Carey Danis & Lowe

New Study Links Prozac & Paxil with Birth Defects

By | Paxil, Pharmaceutical litigation, Prozac, Uncategorized

ssri_birth_defectsA study published in the British Medical Journal links certain antidepressants with birth defects when used by pregnant women. The National Center on Birth Defects and Developmental Disabilities in Atlanta led the study.

Researchers looked at selective serotonin reuptake inhibitors, a class of antidepressants often referred to as SSRIs. The SSRIs included in the study were Paxil, Prozac, Celexa, Lexapro, and Zoloft.

The researchers recorded an increase in birth defects in children whose mothers used Prozac or Paxil early in their pregnancy. They reviewed 28,000 pregnancies between 1997 and 2009.

When women used Paxil one month before or during their first trimester, the risk of birth defects increased. For anencephaly, or a deformation of the skull, the risk rose from 2 per 10,000 to 7 per 10,000. For heart defects, the risk rose from 10 per 10,000 to 24 per 10,000.

In their study, the researchers emphasized that the Prozac and Paxil birth defects risk is small, but their findings do show a link. In light of this link, they called for further studies into the use of SSRI antidepressants in pregnant women.

It is highly recommended to speak with an obstetrician and mental health professional in order to make an informed decision about using SSRI antidepressants during pregnancy.

You are not alone.

At Carey Danis & Lowe, we understand the pain and suffering caused by birth defects. That’s why our team of experienced attorneys works tirelessly to recover losses for families impacted by Prozac birth defects or Paxil birth defects.

Interested in exploring your legal options?

Contact Carey Danis & Lowe today. We offer free case evaluations, during which we discuss your case, your compensation eligibility, and whether filing a Prozac or Paxil birth defects lawsuit is right for you.

You can reach our St. Louis law firm by phone at 800.721.2519, or by completing a confidential personal injury claim form.

We look forward to hearing from you, and offering you any assistance that we can.

Yaz and Yasmin Lawsuit News: Yaz and Yasmin MDL Convened for September Status Conference

By | Pharmaceutical litigation, Uncategorized, Yaz/Yasmin

yaz_lawsuit_yasmin_lawsuit_ocella_lawsuit_settlements_litigation_mdl_lawsuit_settlement_amounts_gallbladder_removal_disease_surgeryThe Yaz and Yasmin multidistrict litigation (MDL) convened for a status conference on September 4, 2013 in the U.S. District Court for the Southern District of Illinois. The court met to discuss updates to the Yaz and Yasmin lawsuits concerning venous thrombosis, or blood clots, and those lawsuits pertaining to arterial embolism.

According to court documents, both parties are currently working together to reach a resolution on the venous thrombosis cases.

The Yaz and Yasmin MDL is In re: Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation MDL No. 2100. It is being heard by Chief Judge David R. Herndon.

The next Yaz and Yasmin MDL status conference has been scheduled for October 30.

Plaintiffs have filed Yaz and Yasmin lawsuits claiming that the contraceptive drugs caused serious harm and injury. The most commonly reported Yaz and Yasmin side effects include venous thrombosis, deep vein thrombosis, pulmonary embolism, heart attacks, and strokes.

According to a U.S. Food and Drug Administration (FDA) warning released in April 2012, data from studies demonstrate a link between the use of Yaz or Yasmin and blood clot formation, especially during the first six months of use. Also, both Yaz and Yasmin contain the hormone drospirenone, which has been associated with an increased risk of blood clot formation.

In a study published by the British Medical Journal in August 2009, researchers compared individuals not using a contraceptive drug to users of a drospirenone-containing contraceptive drug, like Yaz or Yasmin. They found that the risk of blood clot formation rose 6-fold in those using a contraceptive drug containing the hormone drospirenone.

From the evidence currently available, it appears that there is a strong link between venous thrombosis and the use of Yaz and Yasmin.

Carey Danis & Lowe Yaz and Yasmin lawyers represent women who claim to have been harmed by Yaz or Yasmin. Our experienced lawyers are currently accepting Yaz and Yasmin cases. We offer free legal consultations, as well as medical advice from our team of nurses.

We are here to help you achieve justice and resolution.

Contact Carey Danis & Lowe today by calling 800.721.2519, or by submitting a personal injury claim form.

Yaz & Yasmin Lawsuit Update: Australian Women in Beginning Stages of Filing Class Action Lawsuit Against Bayer

By | Pharmaceutical litigation, Uncategorized, Yaz/Yasmin

yaz_lawsuit_yasmin_lawsuit_ocella_lawsuit_settlements_litigation_mdl_lawsuit_settlement_amounts_gallbladder_removal_disease_surgeryIn Australia, women who claim to have been injured by the contraceptive drugs Yaz and Yasmin, both developed and manufactured by Bayer, are in the beginning stages of filing a class action lawsuit. According to an article from The West Australian, two Australian women who have filed a Yaz and Yasmin lawsuit claim that the blood clots in their lungs were the result of taking Bayer’s contraceptives.

One of the women profiled for the article urged increased awareness about the side effects of both contraceptives, as there have been a number of injuries, and even fatalities, linked to Yaz and Yasmin.

The British Medical Journal published a study in 2011 examining the risk of blood clot formation, or venous thrombosis, in patients taking oral contraceptives. The study observed that the risk of blood clot formation increased fivefold when comparing those taking an oral contraceptive and those not taking this type of drug. There is clearly, then, an inherent risk already associated with use of oral contraceptives.

Though according to The British Medical Journal study, some oral contraceptives come with higher risks of blood clot formation than others, such as oral contraceptives containing the hormone levonorgestrel. This type of hormone is found in both Yaz and Yasmin.

In addition to blood clots, other Yaz and Yasmin side effects include heart attack, stroke, deep vein thrombosis (DVT), pulmonary embolism, and brain hemorrhage.

As a national law firm representing women who allege that their injuries and suffering are the result of Yaz or Yasmin use, Carey Danis & Lowe strongly agrees that an increased awareness of the serious Yaz and Yasmin side effects is important and necessary. Carey Danis & Lowe Yaz and Yasmin lawyers work hard to win our clients a day in court and compensation for undue suffering.

If you or someone you love has been injured by Yaz, Yasmin, or Ocella, contact Carey Danis & Lowe for a free legal evaluation and for assistance with filing a Yaz lawsuit, Yasmin lawsuit, or an Ocella lawsuit.

Contact Carey Danis & Lowe by calling 800.721.2519, or by submitting a personal injury claim form.

NuvaRing Lawsuit News: NuvaRing Lawsuits Recently Filed in the U.S. District Court for the Southern District of Illinois

By | NuvaRing, Pharmaceutical litigation, Uncategorized

nuvaringAccording to a recent Madison-St. Clair Record article, NuvaRing lawsuits have recently been filed in the U.S. District Court for the Southern District of Illinois charging five defendants, among them Organon USA, with failure to properly warn healthcare providers and patients about risks of NuvaRing use.

Health complications commonly cited with the use of the NuvaRing contraceptive device include blood clots, deep vein thrombosis (DVT), stroke, heart attack, pulmonary embolism, blood clots, and in some cases, death. According to a Danish study published in May 2012 in the British Medical Journal, researchers discovered that women using a vaginal ring contraceptive device, such as the NuvaRing, experienced a significantly increased risk of developing blood clots.

In addition to the NuvaRing lawsuits in the U.S. District Court in Illinois, there is also a NuvaRing multidistrict litigation (MDL), known as In re: NuvaRing Products Liability Litigation MDL No. 1964, which is being heard in the U.S. District Court of the Eastern District of Missouri. The NuvaRing MDL is being presided over by U.S. District Judge Rodney W. Sippel.

The Madison-St. Clair Record article has deemed the NuvaRing lawsuits recently filed in Illinois “tag-along” lawsuits, meaning they will be significantly influenced by the NuvaRing MDL. NuvaRing attorneys at Carey Danis & Lowe are interested in following the cases in both U.S. District Courts.

Carey Danis & Lowe NuvaRing lawyers continue to hear from women who have been injured by the NuvaRing contraceptive device. Furthermore, they are currently offering free legal evaluations of NuvaRing cases, and can assist in filing a NuvaRing lawsuit.

If you or someone you love has been injured by Organon and Merck’s NuvaRing contraceptive device, contact a pharmaceutical product liability lawyer at Carey Danis & Lowe today. Call Carey Danis & Lowe at 800.721.2519 or submit a personal injury claim form.

Contraceptive Nuvaring Linked to Blood Clots and Stroke

By | NuvaRing, Pharmaceutical litigation, Uncategorized

Published November 12, 2012 by LawsuitInformation.org

Contraceptive Nuvaring Linked to Blood Clots and StrokeNuvaring is a contraceptive device manufactured by Organon. It was approved by the U.S. Food and Drug Administration (FDA) in 2001. Organon developed and manufactured Nuvaring on the premise of introducing a new form of birth control, one that would supposedly be easier for women to use.

However, it soon became apparent after the release of Nuvaring that there were serious issues with the contraceptive device. Questions began to arise as to the verity of Organon’s marketing campaign promoting Nuvaring, especially regarding third-generation hormones and Nuvaring’s unique hormonal release method.

As the Nuvaring is a contraceptive device used as a vaginal insert, the release of hormones into a woman’s body occurs differently than through oral contraceptives, such as birth control pills. Due to the placement of the Nuvaring inside of a woman’s body, the hormones are released directly into the bloodstream.

With oral contraceptives, hormonal release occurs primarily in the digestive tract. It is thought that the direct release of hormones into the bloodstream has been the cause of deadly blood clots in women who have used Nuvaring.

According to a CBS News report released in the fall of 2012, incidents of women suffering from Nuvaring-related blood clots, strokes, pulmonary embolisms, and deep vein thrombosis (DVT) have surpassed 1,000 cases reported to the FDA. The link between Nuvaring and blood clots leading to strokes or death are concurred through a study published by the British Medical Journal in May 2012, which demonstrated a correlation between the use of Nuvarings, and other vaginally inserted, ring-shaped contraceptives, and a 90% increased risk of blood clot development. In June 2012, the New England Journal of Medicine published a study with similar findings.

Trials for Nuvaring lawsuits are set to start on May 6, 2013, according to U.S. Federal District Judge Rodney W. Sippel. A federal Multi-District Litigation (MDL) court has been established in Missouri to hear the Nuvaring lawsuits.

If you have suffered from blood clots, stroke, pulmonary embolism, or DVT as a result of using a Nuvaring, you may be entitled to receive compensation for your undue suffering. Our attorneys at Carey Danis & Lowe are dedicated to assisting clients through providing them with expert legal advice regarding pharmaceutical product liability litigation.

To file a Nuvaring lawsuit, contact an experienced Nuvaring lawyer at Carey Danis & Lowe today.